ArticleBMJ open2025
Functional connectivity-targeted high-definition transcranial infraslow grey noise stimulation for chronic low back pain: protocol for a double-blinded, randomised, controlled clinical trial.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06902233 (High-definition Transcranial Infraslow Gray Noise Stimulation for Treatment of Chronic Low Back Pain), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
High-definition Transcranial Infraslow Gray Noise Stimulation for Treatment of Chronic Low Back Pain: A Double-blinded Randomised Controlled Clinical Trial.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic low back pain (CLBP) is a disabling condition worldwide, with unsatisfactory treatment outcomes, warranting newer therapies. Brain imaging demonstrates altered functional connectivity among three pain processing networks; salience network (SN), default mode network (DMN) and somatomotor network (SMN). Treatments targeted to change the functional connectivity among these networks may produce clinical benefits. This trial will evaluate the efficacy of a novel non-invasive brain stimulation technique targeting the functional connectivity among the SN, DMN and SMN for improving pain intensity in people with CLBP. METHODS AND ANALYSIS: A single-centre double-blinded randomised two-arm placebo-controlled parallel phase II efficacy trial will be conducted at the University of Otago (Dunedin, New Zealand). Participants (n=164) with CLBP will be randomised (1:1) to receive 12 sessions (three per week) of either sham or active stimulation. The primary endpoint will be the change in average pain intensity from baseline to 1 week post completion of intervention. Secondary outcome measures include clinical, functional, psychological, quantitative sensory testing and electroencephalography collected at baseline, 1 week post completion of intervention and at follow-up of 1, 3, and 6 months post intervention. Linear mixed model analyses will be used to evaluate the efficacy of the intervention on the primary outcome. ETHICS AND DISSEMINATION: Ethical approval has been obtained from Northern B Health and Disability Ethics Committee, New Zealand (Ref: 2024 FULL 21891). All participants will provide written informed consent. Findings will be reported to the funding and regulatory bodies, presented at national/international conferences and published in scientific journals. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov, NCT06902233.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.